P914: EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK

• E. Kastritis,
• G. Palladini,
• M. A. Dimopoulos,
• A. Jaccard,
• G. Merlini,
• F. Theodorakakou,
• D. Fotiou,
• M. C. Minnema,
• A. Wechalekar,
• S. Gkolfinopoulos,
• K. Manousou,
• P. Sonneveld,
• S. Schönland

Affiliations

E. Kastritis

1 Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece

G. Palladini

2 Amyloidosis Research and Treatment Center, University of Pavia, Pavia, Italy

M. A. Dimopoulos

1 Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece

A. Jaccard

3 Referral Center for AL amyloidosis, Limoges, France

G. Merlini

2 Amyloidosis Research and Treatment Center, University of Pavia, Pavia, Italy

F. Theodorakakou

1 Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece

D. Fotiou

1 Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece

M. C. Minnema

4 Department of Hematology, University Medical Center Utrecht, Utrecht, Netherlands

A. Wechalekar

5 Clinical Haematology, Cancer Division, University College London Hospital, London, United Kingdom

S. Gkolfinopoulos

6 Health Data Specialists, Dublin, Ireland

K. Manousou

6 Health Data Specialists, Dublin, Ireland

P. Sonneveld

7 Erasmus MC Cancer Institute, Rotterdam, Netherlands

S. Schönland

8 University of Heidelberg, Heidelberg, Germany